Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
NCT00095576
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3000
Enrollment
INDUSTRY
Sponsor class
Conditions
AIDS
HIV Infections
Interventions
BIOLOGICAL:
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
DRUG:
Comparator: placebo
Sponsor
Merck Sharp & Dohme LLC
Collaborators
[object Object]